High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Blood

• Publication date

  2005-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD-2005-03-1301PMID 16105975
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Treatment of multiple myeloma.

  2004cited by this paper
• Drug therapy: Multiple myeloma

  2004cited by this paper
• VTD (Velcade, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed Multiple Myeloma.

  2004cited by this paper
• A phase 2 study of bortezomib in relapsed, refractory myeloma.

  2003cited by this paper
• Treatment of plasma cell dyscrasias with thalidomide and its derivatives.

  2003cited by this paper
• Transplantation for multiple myeloma: who, when, how often? Patient selection and goals.

  2003cited by this paper
• High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

  2003influential reference
• The impact of attaining a minimal disease state after high‐dose melphalan and autologous transplantation for multiple myeloma

  2001cited by this paper
• Increased conventional chemotherapy does not improve survival in multiple myeloma: long-term results of two PETHEMA trials including 914 patients.

  2001cited by this paper
• Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience.

  2001cited by this paper
• Multiple myeloma

  2001cited by this paper
• Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

  2001cited by this paper
• Treatment Approaches for Relapsing and Refractory Multiple Myeloma

  2000cited by this paper
• High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution

  2000cited by this paper
• Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group.

  2000cited by this paper
• Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades

  1999cited by this paper
• Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

  1998cited by this paper
• Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

  1997cited by this paper
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

  1996influential reference
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper
• Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated.

  1996cited by this paper
• Early myeloablative therapy for multiple myeloma.

  1994cited by this paper
• Long-term survival in multiple myeloma.

  1986cited by this paper
• Ten-year survival in multiple myeloma.

  1985cited by this paper
• Long-term survival in multiple myeloma.

  1983cited by this paper
• Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data.

  1973cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• THE TREATMENT OF MULTIPLE MYELOMA

  1948cited by this paper
• Regression Models and Life-Tables

  year unknowncited by this paper

• Melphalan in the biologic era: A 70-year story in hematological malignancies and its legacy, evolution, and future

  2026cites this paper
• Determinants of 15‐Year Progression‐Free Survival in Multiple Myeloma; Real‐World Data From a Single Institution

  2025cites this paper
• Survival Outcomes After Front-Line Consolidation With High-Dose Melphalan and Autologous Stem Cell Transplantation in Younger and Elderly Multiple Myeloma Patients: A Retrospective Bi-Centric Analysis.

  2025cites this paper
• Evolving Strategies in the Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma.

  2024cites this paper
• First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium.

  2024cites this paper
• Transplant in myeloma: who, when, and why?

  2024cites this paper
• Autologous Stem Cell Transplant in Hodgkin’s and Non-Hodgkin’s Lymphoma, Multiple Myeloma, and AL Amyloidosis

  2023cites this paper
• Application of R2-ISS risk stratification to patients with multiple myeloma treated with autologous stem cell transplants at UAMS

  2023cites this paper
• Autologous stem cell transplantation in patients older than 65 years with multiple myeloma: a real-world study

  2023cites this paper
• Total marrow irradiation in hematopoietic stem cell transplantation for hematologic malignancies

  2023cites this paper
• To transplant or not to transplant in multiple myeloma.

  2022cites this paper
• Impact of autologous hematopoietic cell transplantation on disease burden quantified by next‐generation sequencing in multiple myeloma treated with quadruplet therapy

  2022cites this paper
• Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

  2022cites this paper
• Phase 1 study of the combination of escalated total marrow irradiation using helical Tomotherapy and fixed high-dose melphalan (140 mg/m²) followed by autologous stem cell transplantation at first relapse in multiple myeloma.

  2022cites this paper
• Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?

  2022cites this paper
• Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm

  2022cites this paper
• Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real-world study

  2022cites this paper
• Guidelines on the diagnosis, investigation and initial treatment of myeloma: a British Society for Haematology/UK Myeloma Forum Guideline

  2021cites this paper
• Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma

  2021cites this paper
• Pretransplant Determinants of Outcome in Patients with Myeloma Undergoing Autologous Transplantation in Lower Resource Settings

  2021cites this paper
• Race/ethnicity and underlying disease influences hematopoietic stem/progenitor cell mobilization response: A single center experience

  2021cites this paper
• The role of autologous stem-cell transplantation in multiple myeloma in 2021

  2021cites this paper
• Bortezomib‐based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data

  2021cites this paper
• The evolving role and utility of off-label drug use in multiple myeloma

  2021cites this paper
• The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?

  2020cites this paper
• Relapsed/Progressive Disease and Its Prognostic Factors among Multiple Myeloma Patients Receiving Novel Agent Treatment in North East Peninsular Malaysia: A Single Centre Experience

  2020cites this paper
• Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? A review from the Chronic Malignancies Working Party of the EBMT.

  2020cites this paper
• A real‐world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma

  2020cites this paper
• Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study

  2020cites this paper
• Autologous stem cell transplantation is safe and effective for fit, older myeloma patients: exploratory results from the Myeloma XI trial

  2020cites this paper
• Daratumumab subcutaneous formulation for the treatment of multiple myeloma

  2020cites this paper
• Total Marrow Irradiation in Multiple Myeloma: The French Myeloma Group Experience

  2020cites this paper
• Long PFS of more than 7 years is achieved in 9% of myeloma patients in the era of conventional chemotherapy and of first-generation novel anti-myeloma agents: a single-center experience over 20-year period

  2020cites this paper
• Clinical outcomes and prognostic factors in patients with multiple myeloma in South Tyrol: a retrospective single-center analysis

  2020cites this paper
• Total Marrow Irradiation: A Comprehensive Review

  2020cites this paper
• Transplant Pharmacology and Conditioning Therapy

  2020cites this paper
• Mieloma múltiple

  2020cites this paper
• Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy

  2020cites this paper
• Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity 1 with Novel Induction Regimens in Multiple Myeloma.

  2020cites this paper
• Leveraging minimal residual disease to reassess autologous hematopoietic cell transplantation in multiple myeloma

  2020cites this paper
• Banphot Shaengkhamnang1 Pawaret Panyajai1 Sawitree Chiampanichayakul1,4 Singkome Tima1,3,4 Rujirek Chaiwongsa1,4 Tarika Thumvijit2,4 Phennapha Klangsinsirikul1 Adisak Tantiworawit5*

  2020cites this paper
• Recent Advances in the Treatment of Patients with Multiple Myeloma

  2020cites this paper
• The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!

  2020cites this paper
• Pros and cons of frontline autologous transplant in multiple myeloma: the debate over timing.

  2019cites this paper
• Is there still a role for stem cell transplantation in multiple myeloma?

  2019cites this paper
• High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome

  2019cites this paper
• Induction Therapy for Newly Diagnosed Multiple Myeloma.

  2019cites this paper
• A phase I/II study of escalating doses of thalidomide in conjunction with bortezomib and high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in patients with multiple myeloma

  2019cites this paper
• Delaying the use of high-dose melphalan with stem cell rescue in multiple myeloma is ready for prime time.

  2019cites this paper
• Multiple myeloma: Role of autologous transplantation.

  2019cites this paper
• RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group

  2019cites this paper
• Multiple Myeloma

  2019cites this paper
• Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline.

  2019cites this paper
• Hematopoietic Cell Transplantation in Patients With Multiple Myeloma

  2019cites this paper
• Role of Hematopoietic Cell Transplantation for Myeloma

  2018cites this paper
• Treatment of Transplant Eligible Patients with Multiple Myeloma

  2018cites this paper
• High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.

  2018cites this paper
• The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.

  2018cites this paper
• How I treat the young patient with multiple myeloma.

  2018cites this paper
• The challenges of checkpoint inhibition in the treatment of multiple myeloma.

  2018cites this paper
• Dose‐intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients

  2018cites this paper
• Prolonged survival after second autologous transplantation and lenalidomide maintenance for salvage treatment of myeloma patients at first relapse after prior autograft

  2018cites this paper
• The evolution of stem-cell transplantation in multiple myeloma

  2018cites this paper
• Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement

  2018cites this paper
• Poor peripheral blood stem cell mobilization affects long‐term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation

  2018cites this paper
• Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

  2017cites this paper
• Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

  2017cites this paper
• Stem Cell Transplantation in Multiple Myeloma.

  2017cites this paper
• Melphalan hydrochloride for the treatment of multiple myeloma

  2017cites this paper
• Enhancement of death receptor-mediated apoptosis in multiple myeloma cells

  2017cites this paper
• High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma

  2017cites this paper
• Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis

  2017cites this paper
• Multiple myeloma

  2017cites this paper
• Evaluation of low‐dose thalidomide as induction and maintenance therapy in patients with multiple myeloma not eligible for stem cell transplantation

  2017cites this paper
• Autologous Stem Cell Transplantation in Multiple Myeloma in the Era of Novel Drug Induction: A Retrospective Single-Center Analysis

  2017cites this paper
• Impact of induction treatment before autologous stem cell transplantation on long‐term outcome in patients with newly diagnosed multiple myeloma

  2017cites this paper
• High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.

  2016cites this paper
• Transplantation for Multiple Myeloma.

  2016cites this paper
• The role of tandem stem cell transplantation for multiple myeloma patients

  2016cites this paper
• Stem Cell Harvesting after Bortezomib-Based Reinduction for Myeloma Relapsing after Autologous Transplantation: Results from the British Society of Blood and Marrow Transplantation/United Kingdom Myeloma Forum Myeloma X (Intensive) Trial.

  2016cites this paper
• The effect of lipegfilgrastim on hematopoietic reconstitution and supportive treatment after megachemotherapy with autologous peripheral blood stem cell transplantation in patients with lymphoproliferative malignancies

  2016cites this paper
• Prise en charge du myélome multiple : traitement standard et nouveautés thérapeutiques Management of multiple myeloma: current treatment and new therapies

  2016cites this paper
• First line vs delayed transplantation in myeloma: Certainties and controversies.

  2016cites this paper
• Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity

  2016cites this paper
• The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modern multiple myeloma therapy.

  2016cites this paper
• Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.

  2016cites this paper
• A Phase I/II Study of Escalating Doses of Bortezomib in Conjunction with High-Dose Melphalan as a Conditioning Regimen for Salvage Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma.

  2016cites this paper
• A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT

  2016cites this paper
• Controversies in multiple myeloma: Evidence-based update.

  2016cites this paper
• Management of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma.

  2016cites this paper
• A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy

  2016cites this paper
• Jean-Luc Harousseau

  2016cites this paper
• Autologous stem cell transplantation for multiple myeloma: Long-term results.

  2016cites this paper
• Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up

  2016cites this paper
• Early Versus Delayed Autologous Stem Cell Transplantation and Interferon Maintenance in Multiple Myeloma: Single-Center Experience of 18 Years.

  2016cites this paper
• Effect of melphalan 140 mg/m2 vs 200 mg/m2 on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation—a single center experience

  2016cites this paper
• Treatment for patients with newly diagnosed multiple myeloma in 2015.

  2015cites this paper
• THERAPY FOR MULTIPLE MYELOMA - HISTORICAL PERSPECTIVE: REVIEW OF LITERATURE

  2015cites this paper
• Biological markers and treatment as prognostic factors in multiple myeloma

  2015cites this paper
• Autologous Stem Cell Transplantation Is an Effective Salvage Therapy for Primary Refractory Multiple Myeloma.

  2015cites this paper